Study #2020-0948
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies
MD Anderson Study Status
Not Accepting
Treatment Agent
Sym024, Sym021
Description
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Cancer, Solid Tumor
Study phase:
Phase I
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.